#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma

byTeddy Guo

February 11, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract Multiple Cereblon genetic alterations were associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

RelatedReports

StudyGraphics

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

April 28, 2022

StudyGraphics

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

April 14, 2022

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

StudyGraphics

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

April 13, 2022

StudyGraphics

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

April 12, 2022

Preterm infants responsive to PCV13 vaccine

Increasing vaccine coverage in low and middle-income countries may prevent over 30 million deaths between 2020 to 2030

Complement mutation linked to poor response to eculizumab

Acute neurologic manifestations in children with hemolytic uremic syndrome linked to increased mortality

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Large study outlines risk factors for severe COVID-19 in children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

#VisualAbstract Multiple Cereblon genetic alterations were associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Increasing vaccine coverage in low and middle-income countries may prevent over 30 million deaths between 2020 to 2030

RelatedReports

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

#VisualAbstract: Melanoma is projected to remain an important global health concern in 2040, with high incidence rates in fair-skinned populations of European descent

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

Increasing vaccine coverage in low and middle-income countries may prevent over 30 million deaths between 2020 to 2030

Acute neurologic manifestations in children with hemolytic uremic syndrome linked to increased mortality

Large study outlines risk factors for severe COVID-19 in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get 2MM+ Premium Access

Recent Reports

#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma

RELATED REPORTS

#VisualAbstract Multiple Cereblon genetic alterations were associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Increasing vaccine coverage in low and middle-income countries may prevent over 30 million deaths between 2020 to 2030

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get 2MM+ Premium Access

Recent Reports